|
|
||||||||
Published online before print May 17, 2006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||



* Laboratory of Toxicology, Department of Pharmacological Sciences, University of Milan, Italy; and
Department of Experimental and Applied Pharmacology, University of Pavia, Italy
1Correspondence: Laboratory of Toxicology, Department of Pharmacological Sciences, Faculty of Pharmacy, Via Balzaretti 9, 20133 Milan, Italy. E-mail: emanuela.corsini{at}unimi.it
| ABSTRACT |
|---|
|
|
|---|
(TNF-
), increased PHA-induced interleukin-10 (IL-10) release, and similar PHA-induced interferon-
production were observed in elderly subjects compared with young volunteers. Lower antibody titer to influenza A virus was observed in elderly individuals, and the seroconversion factor was found to be correlated inversely with IL-10 production and correlated directly with TNF-
production and to a lesser extent, with the plasma level of DHEA. These results suggest that altered cytokine production in elderly subjects at the moment of vaccination can be predictive of a low response to influenza vaccination and warrant the study of strategies to improve protection afforded by the use of vaccines.
Key Words: immunosenescence cytokines dehydroepiandrosterone aging
| INTRODUCTION |
|---|
|
|
|---|
Given the increasing proportion of elderly people worldwide, a better understanding of the causes and mechanisms of immunosenescence is crucial to identify whether prevention might be beneficial to enhance quality of life and to reduce the cost of medical care in old age. Normal aging is indeed associated with a number of impaired immune responsiveness, such as reduction in response to recall antigen, alterations in T cell functions, which contribute to increased vulnerability to infectious disease and malignancy, and reduced responses to preventive vaccination in the elderly [4 ].
Today, in developed countries, influenza prophylaxis depends on the annual administration of a killed, trivalent influenza vaccine tailored each year to specific strains of the influenza virus. Vaccine is recommended for all individuals with chronic, underlying diseases and for those aged 65 years or older. Unfortunately, the present available influenza virus vaccine fails to generate protective immunity in
50% of old individuals [5
]. In particular, the seroconversion, after vaccine, is 50% from 60 to 70 years old, 31% from 70 to 80 years old, and only 11% after the age of 80. Yet, as far as public health is concerned, the vaccination reduces the morbidity by 25%, admission to hospital by 20%, pneumonia by 50%, and mortality by 70% [6
].
Improved vaccines or pharmacological intervention, which can overcome the decline in immune function with aging and/or induce broader immunity to novel pandemic strains, are considered a high priority [7 , 8 ].
Many factors contribute to immunosenescence, including stem-cell defects, thymus involution, aging of resting immune cells, replicative senescence of clonally expanding cell, defects in antigen-presenting cells (APC), dysfunction in several signal transduction pathways, and dysregulation of the cytokine network [9 10 11 ]. We have recently shown in rodents and humans that a decreased expression in receptor for activated C kinase 1 (RACK-1), in the absence of differences in the expression of total protein kinase C (PKC) isoforms, underlies defective PKC activation and functional immune impairment with aging, such as cytokine production and proliferation [12 , 13 ]. Furthermore, we found a positive correlation between plasma level of dehydroepindrosterone (DHEA), whose levels decrease with aging [14 ], and RACK-1 immunoreactivity, suggesting an important role of this hormone in maintaining RACK-1 expression and PKCß-mediated immune activation in leukocytes [12 , 13 ].
Our understanding of the molecular mechanism of the immune response to influenza virus is still incomplete. During infection, the influenza virus interacts with airway cells, inducing the release of immunoreactive mediators, which attract inflammatory cells to the sites of infection and exert antiviral activities, providing an early defense against viral infection. Many cytokines are produced, involved in the initiation of the inflammatory response in addition to the recruitment and activation of specific lymphocytes (reviewed in refs. [15
, 16
]). The interplay with interleukin (IL)-1ß, tumor necrosis factor
(TNF-
), interferon (IFN)-
/ß, IL-18, IFN-
, and chemokines forms a complex, positive feed-back network leading to inflammatory response and the development of influenza-specific, cell-mediated immunity. Cytokine gene expression is associated with the activation of several signal transduction molecules, i.e., nuclear factor-
B, activated protein-1, signal transducer and activator of transcription, and IFN-regulatory factor, many of which are dependent on PKC activation [17
18
19
].
The purpose of the present study was to investigate if the age-related impairment of the translocation of PKC, which underlies downstream defects in the in vitro activation of immune responses, was also relevant for the in vivo immune responsiveness, as assessed by response to influenza vaccination. We tested the hypothesis that an altered function of immune cells at the moment of vaccination may be in part responsible for a defective response to the vaccine in the elderly. We therefore investigated the correlation between DHEA, cortisol plasma levels, and in vitro cytokine production at the moment of vaccination with antibody response to influenza vaccination in young and old, healthy volunteers. As a result of their central role in regulating the immune response, including viral infection, we investigated the production of TNF-
, IL-10, and IFN-
in response to nonantigen-specific stimuli, such as lipopolysaccharide (LPS) and phytohemagglutinin (PHA), using the whole blood assay, which is a simple method that reproduces the natural environment (autologous serum). It was used, as it requires less blood, and the risk of loss of minor lymphocyte subsets through density gradient is eliminated [20
].
Overall, our study indicates that low plasma level of DHEA, decreased TNF-
, and increased IL-10 production at the moment of vaccination are associated with lower antibody response to influenza vaccination and suggest possible means of pharmacological modulation of immune functions in the elderly.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Study protocol
In this study, a total of 66 healthy subjects living in the same geographical area of Northern Italy were recruited. These subjects included 52 elderly subjects (age 73.2±6.9 years, range 6385; 37 females and 15 males) and 14 young subjects (age 30.4±4.8 years, range 2641, nine females and five males). All elderly subjects were functionally independent. The ethical committee of the local Health Authorities approved the study, and all subjects signed an informed consent. All the clinical procedures and enrollment of the subjects were performed according to the guidelines of the Italian Health Authorities and the Declaration of Helsinki principles. Criteria for exclusion were abnormal laboratory values, medication known to affect the immune system (i.e., steroids), or patients suffering from malignancies, inflammations, and infections.
Prevaccination blood samples were collected just prior to vaccination in the early morning. Subjects were vaccinated in November 2004 by intramuscular injection with a commercially available, trivalent 2004/2005 influenza vaccine containing 15 µg haemagglutinin of each of the following strains: A/New Caledonian/20/99 (H1N1), A/Fujian/411/2002 (H3N2), and B/Shangai/361/2002. Postvaccination sera were collected 18 days after vaccination at the same hour. Serum samples were separated into aliquots and stored at 20°C until assayed. Over 95% of the subject population had received yearly influenza immunization for the past 3 years as part of their routine clinical preventive care.
Preparation of whole blood cells and cytokine production
Blood samples were taken by venous puncture with sodium citrate 0.5 M as anticoagulant. Sodium citrate was chosen instead of heparin or EDTA as anticoagulant, as functional assays were performed using the whole blood assay, and heparin may be contaminated with endotoxin; EDTA interferes with cell activation. Blood samples were diluted 1:10 in cell culture medium RPMI 1640 (Sigma Chemical Co.) containing 2 mM L-glutamine, 0.1 mg/ml streptomycin, 100 IU/ml penicillin. Diluted blood samples were treated in the presence or absence of LPS at a final concentration of 1 µg/ml or PHA, 1.2 µg/ml, and incubated for 24 h or 96 h at 37°C in a humidified 5% CO2 incubator for TNF-
and IL-10, IFN-
release, respectively. As a result of the variability in stimulation assays, the same lot of each reagent was used in all experiments. Cell-free supernatants obtained by centrifugation at 1200 revolutions per minute for 5 min were stored at 20°C until measurement. Cytokine production was assessed by enzyme-linked immunosorbent assay (ELISA) using commercially available kits (Immunotools, Friesoythe, Germany). Results are expressed in pg/ml.
Assay for DHEA and cortisol
The levels of DHEA and cortisol in human plasma were determined by a commercially available enzyme immunoassay (Assay Design, Inc., Ann Arbor, MI) following the suppliers instructions. Results are expressed as ng/ml.
Anti-influenza antibody assay
Pre- and postvaccination immunoglobulin G antibody levels to Influenza A virus (H3N2) were assessed using a commercially available ELISA kit (Adaltis Italia, Casalecchio di Reno, Italy). Paired pre- and postvaccination sera samples from the same individual were tested simultaneously. Results are expressed as antibody titer, calculated using the semiquantitative plot enclosed in the kit and as the seroconversion factor, which was calculated as the ratio of the mean titer before vaccination:titer after vaccination.
Western blot analysis
For RACK-1 and ß-actin expression in leukocytes, 1.0 ml blood was treated with ammonium chloride to remove red cells, and then the remaining leukocytes were lysed in 100 µl homogenization buffer (50 mM Tris, 150 mM NaCl, 5 mM EDTA, pH 7.5, 0.5% Triton X-100, 50 µM phenylmethylsulfonyl fluoride, 2 µg/mL aprotinin, 1 µg/mL pepstatin, and 1 µg/mL leupeptin) and denatured for 10 min at 100°C [21
]. The protein content of the cell lysate was measured using a commercial kit (Bio-Rad). The cell proteins (30 µg) were electrophoresed into a 12% sodium dodecyl sulfate-polyacrylamide gel under reducing conditions. The proteins were then transferred to polyvinylidene difluoride membranes (Amersham, Little Chalfont, UK). The different proteins were visualized using RACK-1 (1:2500) and ß-actin (1:5000) primary antibodies and developed using enhanced chemiluminescence (Amersham). The image of the immunoblotting was acquired with a Nikon charged-coupled device video camera module. The optical density of the bands was calculated and analyzed by means of the Image 1.47 program for digital image processing (Wayne Rasband, Research Service Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD).
Statistical analysis
Data are expressed as mean ± SEM. Statistical analysis was performed using GraphPad InStat Version 3.0a for Macintosh (GraphPad Software, San Diego, CA). Statistical differences were determined using the unpaired t-test or a multiple comparison test, as indicated in the legends. Spearman correlation was used to analyze the correlation among different parameters considered. Effects were designated significant if P
0.05.
| RESULTS |
|---|
|
|
|---|
|
|
, IL-10, and IFN-
was evaluated after in vitro stimulation of whole blood with LPS and PHA. The optimal time and stimuli concentrations were identified in preliminary experiments for each cytokine. For TNF-
production, cells were stimulated for 24 h with 1 µg/ml LPS, and for IL-10 and IFN-
, cells were stimulated for 96 h with 1.2 µg/ml PHA. The spontaneous release of all cytokines investigated as well as their plasma levels were below the limit of detection before and after vaccination (data not shown). Figure 2
shows the production of TNF-
, IL-10, and IFN-
by blood cells in young and elderly at the moment of influenza vaccination. The elderly subjects were indeed characterized by altered cytokine production. A statistically significant decrease in LPS-induced TNF-
release (from 1152±185 in the young to 799±80 pg/ml in the elderly, P=0.0495), a statistically significant increase in PHA-induced IL-10 release (from 97±54.7 to 458±34 pg/ml, P<0.0001), and similar IFN-
release compared with young subjects (4688±424 and 4208±252 pg/ml in young and elderly, respectively) were observed. IL-10 and IFN-
production was also assessed following 96 h stimulation with LPS. As observed for stimulation with PHA, LPS-induced IL-10 production was increased in the elderly (from 12±4 pg/ml in the young to 51±20 pg/ml in the elderly, P=0.0108). On the contrary, LPS-induced IFN-
production was reduced significantly in the elderly (from 421±29 pg/ml in the young to 120±7 pg/ml in the elderly, P=0.0074).
|
production or with cortisol level (not shown). Finally, the decreased TNF production was correlated to plasma levels of DHEA (linear correlation r=0.326, P=0.0076; not shown), and IL-10 release was strongly correlated (inverse correlation r=0.490, P<0.0001) with the plasma levels of DHEA (Fig. 4
).
|
|
| DISCUSSION |
|---|
|
|
|---|
, and increased IL-10 production at the moment of vaccination are associated with lower antibody response to influenza vaccination.
The senescent immune system displays reduced responsiveness, and this has to be overcome if therapeutic vaccination is to be of benefit for the patient. Although the defects are quite well-characterized, the molecular mechanisms, inducing and sustaining immunosenescence and ways to overcome them, are still to be explored in more detail. Substantial data from animal studies have demonstrated a stimulatory effect of DHEA on immune function. We previously demonstrated in vitro and in vivo that DHEA can restore the age-related, defective TNF-
production in macrophages and mitogen-induced splenocyte proliferation [12
]. May et al. [23
] demonstrated that DHEA administration reversed corticosteroid and stress-induced inhibition of immune function, Loria et al. [24
] showed that DHEA administration has a protective effect against systemic Coxsackie virus and Herpes simplex type 2 encephalitis, and Daynes et al. [25
] found that it can enhance IL-2 production by activated murine T cells. In a limited clinical trial, it has been demonstrated that orally administered DHEA (50 mg/daily) to elderly men with low-serum DHEA safely activated several immune functions within 220 weeks of treatment, including B and T cell mitogenic response and PHA-induced IL-2 production, suggesting potential therapeutic benefits of DHEA supplementation in immunodeficient states [26
]. On the contrary, although highly effective in sustaining the response to vaccination in aged rodents, a short course of DHEA treatment, 2 days prior and 2 days after vaccination, failed to improve the age-related, declined response to influenza vaccination in elderly human subjects [27
]. Overall, too little is known about the effects of DHEA supplementation on the human immune system, and it is still premature to relate these findings to routine clinical applications. Nevertheless, in our investigation, higher baseline DHEA levels were predictive of better immunization against influenza and may suggest that DHEA supplementation may be beneficial. Other methods of increasing immune response in the elderly to influenza vaccine may include the addition of IL-2 to vaccine protocol, the use of liposome carriers or diphtheria toxoid adjuvants, or using alternative routes of immunization [28
29
30
31
].
Concerning the immune system functionality, age-related changes in cytokine production by immune cells are likely to contribute to the decreased antibody production seen after influenza vaccination in the elderly. Numerous studies have investigated the age-related change in cytokine production after specific and nonspecific stimulation, and contradictory results have been reported [32
33
34
]. This may be a result of sample sizes, varying states of health and lifestyle, different stimuli, and culture conditions. Results from our investigation show decreased TNF-
production, unchanged PHA-induced IFN-
production, and decreased LPS-induced IFN-
production in the elderly, together with increased mitogen-induced IL-10 production. IL-10 and TNF-
are cytokines, which have complex and predominantly opposing roles in the activation of the immune response [35
, 36
]. The increased production of IL-10 in the elderly, observed in response to LPS and PHA, is likely to inhibit the maturation of APC, hampering, together with decreased TNF-
production, their migration to draining lymph nodes, compromising the subsequent induction of the specific immune response. Furthermore, IL-10 can induce long-term, antigen-specific anergy in CD4+ T cells. Thus, it is intriguing that the possession of an anti-inflammatory genotype (high IL-10 and low TNF-
production) is increased significantly in male centenarians [37
]. High TNF-
production may be an important and necessary part of the normal host response to pathogens, but its overproduction may cause immune-inflammatory diseases and eventually death. An anti-inflammatory phenotype (high IL-10 production) may be highly advantageous in the last decades of life, owing to the chronic proinflammatory status, which develops in the subjects with age [37
, 38
]. Thus, it is tempting to speculate that the presence of "high IL-10/low TNF-
" could be favorable in protecting against age-related diseases, particularly, neurodegenerative diseases [39
, 40
], but conversely, it could hamper the immune response to infections and vaccine.
Overall, our study contributes to the understanding of the effects of age on innate and adaptive immunity, which accompany the response to influenza vaccine. It represents an important bridge between basic immune function and clinical immunology in the hope of generating an effective reconstitution to improve immune response in the elderly. The results obtained may contribute to define better strategies to improve the response to vaccination in the elderly and underlie the necessity to overcome immunosenescence at the moment of vaccination to obtain a better response.
| ACKNOWLEDGEMENTS |
|---|
Received March 13, 2006; revised April 9, 2006; accepted April 10, 2006.
| REFERENCES |
|---|
|
|
|---|
B signaling in lymphocytes: a new cast of characters J. Cell Sci. 117,31-39
, IL-6, IFN-
and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation Cytokine 4,239-248[CrossRef][Medline]
308 promoter SNP J. Med. Genet. 40,296-299
and risk of Alzheimers disease and vascular dementia: a case control study Lancet 357,436-439[CrossRef][Medline]This article has been cited by other articles:
![]() |
H. M. Kim, Y.-W. Lee, K.-J. Lee, H. S. Kim, S. W. Cho, N. van Rooijen, Y. Guan, and S. H. Seo Alveolar Macrophages Are Indispensable for Controlling Influenza Viruses in Lungs of Pigs J. Virol., May 1, 2008; 82(9): 4265 - 4274. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Li, L. G. Cowden, J. D. King, D. A. Briles, H. W. Schroeder Jr, A. B. Stevens, R. T. Perry, Z. Chen, M. S. Simmons, H. W. Wiener, et al. Effects of Chronic Stress and Interleukin-10 Gene Polymorphisms on Antibody Response to Tetanus Vaccine in Family Caregivers of Patients With Alzheimer's Disease Psychosom Med, July 1, 2007; 69(6): 551 - 559. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. T. Keylock, T. Lowder, K. A. Leifheit, M. Cook, R. A. Mariani, K. Ross, K. Kim, K. Chapman-Novakofski, E. McAuley, and J. A. Woods Higher antibody, but not cell-mediated, responses to vaccination in high physically fit elderly J Appl Physiol, March 1, 2007; 102(3): 1090 - 1098. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |